News Bayer's asundexian starts EU review for ischaemic stroke The EMA has started its review of Bayer's asundexian for secondary stroke prevention, keeping it ahead of a rival drug from BMS and J&J.
News Bayer gets swift review for Kerendia in type 1 diabetes FDA starts a priority review of Bayer's Kerendia for chronic kidney disease in type 1 diabetes, which could end a 30-year drought in new therapies.
News Bayer plans filings for cardiac amyloidosis imaging agent Armed with new phase 3 data, Bayer is preparing to file a PET imaging agent that could accelerate the diagnosis of cardiac amyloidosis.
News Bayer returns to M&A with $2.45bn Perfuse Therapeutics deal Bayer has agreed terms for its first biopharma takeover in years, paying $300m upfront for Perfuse and its novel drug implant for eye diseases.
News Amazon launches its AI drug discovery platform Amazon has pitched an AI-powered drug discovery platform to the biopharma industry that combines in silico and wet-lab work in a single application.
News Data builds behind Bayer's Kerendia in kidney disease Bayer's Kerendia has hit the spot in another phase 3 trial that could fuel its already rapid growth as a chronic kidney disease treatment.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.